J&J drug reduces risk of prostate cancer spread and death in late-stage study - Daily Monitor

J&J drug reduces risk of prostate cancer spread and death in late-stage study    Daily Monitor New J&J drug combo delays extra prostate cancer treatment by years    Stock Titan Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death | Newswise    Newswise ASCO26: J&J's Erleada offers new treatment approach for localised high-risk prostate cancer    FirstWord Pharma For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds    statnews.com

Original source: Google News